Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 25, 2017 - Issue 1
Submit an article Journal homepage
439
Views
31
CrossRef citations to date
0
Altmetric
Original Articles

Interferon Alpha-2a Therapy in Patients with Refractory Behçet Uveitis

Murat HasanreisogluDepartment of Ophthalmology, School of Medicine, Gazi University, Ankara, TurkeyCorrespondence[email protected]
, MD,
Mehmet Ozgur CubukDepartment of Ophthalmology, School of Medicine, Gazi University, Ankara, Turkey
, MD,
Sengul OzdekDepartment of Ophthalmology, School of Medicine, Gazi University, Ankara, Turkey
, MD,
Gokhan GurelikDepartment of Ophthalmology, School of Medicine, Gazi University, Ankara, Turkey
, MD,
Zeynep AktasDepartment of Ophthalmology, School of Medicine, Gazi University, Ankara, Turkey
, MD &
Berati HasanreisogluDepartment of Ophthalmology, School of Medicine, Gazi University, Ankara, Turkey
, MD
Pages 71-75 | Received 27 Apr 2014, Accepted 14 Dec 2015, Published online: 24 Feb 2016

REFERENCES

  • Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138:373–380.
  • Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008; 67:1656–1662.
  • Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet’s disease. Lancet. 1989;1:1093–1096.
  • Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med. 1990;322:281–285.
  • Kotter I, Durk H, Saal J, et al. Therapy of Behçet’s disease. Ger J Ophthalmol. 1996;5:92–97.
  • Yazici H, Ozyazgan Y. Medical management of Behçet’s syndrome. Dev Ophthalmol. 1999;31:118–131.
  • Kotter I, Gunaydin I, Zierhut M, et al. The use of interferon alpha in Behçet disease: review of the literature. Semin Arthritis Rheum. 2004;33:320–335.
  • Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease. Lancet. 1990;335:1078–1080.
  • Krause L, Altenburg A, Pleyer U, et al. Longterm visual prognosis of patients with ocular Adamantiades-Behçet’s disease treated with interferon-alpha-2a. J Rheumatol. 2008;35:896–903.
  • Kotter I, Zierhut M, Eckstein A, et al. Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behçet’s disease with sight-threatening retinal vasculitis. Adv Exp Med Biol. 2003;528:521–523.
  • Tsambaos D, Eichelberg D, Goos M. Behçet’s syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res. 1986;278:335–336.
  • Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002;138:467–471.
  • Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol. 2007;91:335–339.
  • Deuter CM, Zierhut M, Mohle A, et al. Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behçet’s disease. Arthritis Rheum. 2010;62:2796–2805.
  • Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol. 2006; 244:1692–1695.
  • Yalcindag FN, Uzun A. Results of interferon alpha-2a therapy in patients with Behçet’s disease. J Ocul Pharmacol Ther. 2012;28:439–443.
  • Gueudry J, Wechsler B, Terrada C, et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease. Am J Ophthalmol. 2008;146:837–844.
  • Kotter I, Deuter C, Stubiger N, et al. Interferon-a (IFN-a) application versus tumor necrosis factor-a antagonism for ocular Behçet’s disease: focusing more on IFN. J Rheumatol. 2005;32:1633; author reply 1634.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.